Hand foot syndrome associated with docetaxel treatment in metastatic prostate cancer: A case report
PDF
Cite
Share
Request
Case report
P: 280-282
2017

Hand foot syndrome associated with docetaxel treatment in metastatic prostate cancer: A case report

Acta Haematol Oncol Turc 2017;50(3):280-282
1. Department of Medical Oncology, Selcuk University, Konya, Turkey
2.
No information available.
No information available
Received Date: 2017-05-24T14:55:06
Accepted Date: 2017-12-19T16:13:12
PDF
Cite
Share
Request

Abstract

Prostate cancer is one of the most common tumors in men. Docetaxel and prednisone treatment are accepted as standard chemotherapy in prostate cancer patients. Docetaxel is a chemotherapeutic drug of the taxane group that inhibits the depolymerization of tubulin and has an antitumoral effect through the stabilization of microtubules. It has also been reported that docetaxel therapy lead to cutaneous side effects besides systemic side effects. The most common cutaneous side effects of docetaxel are alopecia, hand foot syndrome, fixed plaque erythrodysesthesia, nail changes. Hand foot syndrome can be confronted with clinical tables ranging from bilateral, symmetrical erythema to desquamated plaques on hands and feet. It has been reported that hand foot syndrome occurred in the following weeks or months of chemotherapy treatment. We would like to present our case of hand foot syndrome associated with docetaxel chemotherapy treatment which is commonly used in patients with metastatic prostate cancer.